Trial Profile
A Randomized Controlled Trial of the Endeavor Resolute Zotarolimus-Eluting Stent Versus the Cypher Sirolimus-Eluting Stent for Percutaneous Coronary Intervention in a Real-World All-comer Patient Population in China.
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 20 Oct 2017
Price :
$35
*
At a glance
- Drugs Sirolimus (Primary) ; Zotarolimus (Primary)
- Indications Coronary artery disease; Coronary artery restenosis
- Focus Therapeutic Use
- Acronyms R-China RCT
- Sponsors Medtronic
- 16 Oct 2017 Status changed from active, no longer recruiting to completed.
- 17 Jan 2012 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 29 Sep 2011 Actual initiation date (September 2011) added as reported by ClinicalTrials.gov.